Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
Want to see SNSE full AI Analyst Report?
Top Page
Sensei Biotherapeutics
(NASDAQ:SNSE)
Select Model
Select Model
Rating:41Neutral
Price Target:
$12.50
▲(9.46% Upside)
Action:Reiterated
Date:06/11/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses/cash burn, and negative equity in TTM), reinforced by bearish technicals with price below all major moving averages. Valuation provides limited support due to negative earnings, and recent capital-structure changes increase dilution risk.
Positive Factors
Engineered biologics platform
Sensei’s focused platform on engineered antibody- and cytokine-based immunotherapies for solid tumors is a durable strategic asset. A modular biologics approach can spawn multiple clinical candidates, supports iterative optimization, and makes the company a more attractive partner for co-development or licensing over time.
Negative Factors
No revenue; ongoing cash burn
Operating with essentially zero product revenue and persistent negative operating and free cash flow forces continual dependence on external financing. This structural cash burn elevates execution risk, compresses runway absent sizable financing, and repeatedly exposes investors to dilution over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Engineered biologics platform
Sensei’s focused platform on engineered antibody- and cytokine-based immunotherapies for solid tumors is a durable strategic asset. A modular biologics approach can spawn multiple clinical candidates, supports iterative optimization, and makes the company a more attractive partner for co-development or licensing over time.
Read all positive factors
Sensei Biotherapeutics (SNSE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.45M
Dividend YieldN/A
Average Volume (3M)38.93K
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue GrowthN/A
EPS Growth19.36%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-147.90
Shares Outstanding1,341,941
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap-7.05
Enterprise Value/Revenue25.34
Enterprise Value/Gross Profit0.92
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$53.33Price Target Upside367.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-81.89
Revenue Forecast (FY)N/A
Sensei Biotherapeutics Business Overview & Revenue Model
Company Description
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. This immunoth...
How the Company Makes Money
Sensei Biotherapeutics does not have publicly disclosed, recurring revenue from commercial product sales because its programs are in clinical development rather than marketed. As a result, to the extent revenue is reported, it would generally be e...
Sensei Biotherapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -132.96M | 0.00 | -551.00K | -571.00K | -1.81M | -685.00K |
| EBITDA | -184.33M | -20.91M | -29.52M | -33.39M | -46.56M | -35.44M |
| Net Income | -184.46M | -21.09M | -30.16M | -34.10M | -48.59M | -36.79M |
Balance Sheet | ||||||
| Total Assets | 205.38M | 22.90M | 45.36M | 74.37M | 118.38M | 153.22M |
| Cash, Cash Equivalents and Short-Term Investments | 202.79M | 21.18M | 41.34M | 65.76M | 107.12M | 147.62M |
| Total Debt | 1.04M | 1.51M | 3.85M | 6.21M | 8.03M | 2.35M |
| Total Liabilities | 14.19M | 4.31M | 6.97M | 9.48M | 14.97M | 6.71M |
| Stockholders Equity | 191.19M | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M |
Cash Flow | ||||||
| Free Cash Flow | -24.11M | -20.47M | -24.82M | -32.20M | -39.35M | -32.28M |
| Operating Cash Flow | -24.09M | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M |
| Investing Cash Flow | -18.86M | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M |
| Financing Cash Flow | 185.40M | -645.00K | -787.00K | -11.17M | -287.00K | 163.94M |
Sensei Biotherapeutics Technical Analysis
Negative
11.42
Price Trends
23.38
Negative
22.92
Negative
16.25
Negative
Market Momentum
-3.09
Positive
35.60
Neutral
8.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Negative. The current price of 11.42 is below the 20-day moving average (MA) of 16.28, below the 50-day MA of 23.38, and below the 200-day MA of 16.25, indicating a bearish trend. The MACD of -3.09 indicates Positive momentum. The RSI at 35.60 is Neutral, neither overbought nor oversold. The STOCH value of 8.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNSE.
Sensei Biotherapeutics Risk Analysis
Sensei Biotherapeutics disclosed 82 risk factors in its most recent earnings report. Sensei Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensei Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $17.82M | -0.45 | -248.91% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $13.72M | -1.55 | -94.94% | ― | ― | 53.06% | |
45 Neutral | $8.98M | -0.29 | -423.84% | ― | -8.47% | 25.61% | |
41 Neutral | $17.45M | -0.09 | -83.59% | ― | ― | 19.36% | |
40 Underperform | $8.76M | -0.29 | -97.58% | ― | 78.64% | 50.70% |
* Healthcare Sector Average
SNSE
Sensei Biotherapeutics
13.00
6.48
99.39%
CLRB
Cellectar Biosciences
2.23
-9.24
-80.56%
COCP
Cocrystal Pharma
0.99
-0.47
-31.92%
BRTX
BioRestorative Therapies
0.35
-1.27
-78.27%
BOLT
Bolt Biotherapeutics
4.56
-1.21
-20.97%
Sensei Biotherapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Sensei Biotherapeutics Overhauls Capital Structure at 2026 Meeting
Positive
Jun 10, 2026
On June 10, 2026, Sensei Biotherapeutics held its 2026 annual meeting of stockholders, where investors approved new 2026 equity incentive and employee stock purchase plans with automatic annual share increases through 2036, significantly expanding...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Sensei Biotherapeutics Updates 2026 Board Reconstitution Plans
Neutral
May 22, 2026
On May 22, 2026, Sensei Biotherapeutics, Inc. announced changes to its planned board reconstitution ahead of its 2026 Annual Meeting of Stockholders scheduled for June 10, 2026. Due to personal reasons, incoming director Karen Vousden, Ph.D., aske...
Financial DisclosuresM&A TransactionsPrivate Placements and FinancingShareholder Meetings
Sensei Biotherapeutics Sets Vote on Series B Conversion
Neutral
May 21, 2026
Sensei Biotherapeutics has scheduled its 2026 annual shareholder meeting for June 10, 2026, where investors will vote on converting its Series B Non-Voting Convertible Preferred Stock into common shares, a move that would issue more than 20% new e...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Sensei Biotherapeutics Announces Leadership and Board Transitions
Neutral
Apr 16, 2026
On April 10, 2026, Sensei Biotherapeutics disclosed that three directors tendered conditional resignations effective two business days after the June 10, 2026 annual meeting, contingent on stockholder approval of proposals that would permit conver...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.